October 1st 2023
Check out important news you might have missed including the expanded indication for remdesivir to those with severe hepatic impairment; a small study shows that SARS-CoV-2 infects coronary arteries and increases plaque Inflammation; and some antibiotics are associated with C diff Infection.
NSAIDs Combine with CDI Toxins to Damage Mitochondria in Colonic Epithelial Cells
August 3rd 2023Nonsteroidal anti-inflammatory drugs can work with Clostridioides difficile toxins to target mitochondria of epithelial cells, leading to increased severity of infection that can be long-lasting.
Read More
The Future of COVID-19 Vaccines, and Other Top Stories This Week
June 16th 2023This week, the FDA’s vaccine advisory committee unanimously voted the next generation of COVID-19 vaccines should be updated to a monovalent XBB strain. Read all about this and other top infectious disease headlines.
Read More
Rising Threat: Evaluating Salmonella Treatment Options Amid Antimicrobial Resistance
May 15th 2023Empiric therapy for severe Salmonella disease remains effective, but fluoroquinolone resistance calls for a shift towards trimethoprim-sulfamethoxazole as the preferred oral treatment for non-severe cases.
Read More
Patient Perspectives on Rectal Administration for Recurrent C difficile Infection
May 15th 2023A study of patients with recurrent Clostridioides difficile infection (rCDI) found that Rebyota, a rectally administered live biotherapeutic, was considered easy, quick, and appealing due to the lack of bowel preparation.
Read More
Seres Shares Trial Data for Vowst, the FDA-Approved Microbiome Therapeutic
May 8th 2023Recent phase 3 trial data for Vowst showed the microbiota-based therapeutic prevented recurrent C difficile infection in 91.3% of recipients after 8 weeks, a response that 94.6% of these patients maintained through week 24.
Read More